



REGULATED INFORMATION

**PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF
2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS
(THE “TRANSPARENCY LAW”)**

GHENT, Belgium, 6 October 2017 – **Ablynx [Euronext Brussels: ABLX; OTC: ABYLY]** today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Consonance CapMan GP LLP on 4 October 2017.

Consonance CapMan GP LLP notified Ablynx that they have crossed the 3% threshold as of 3 October 2017 and now hold a total of 2,207,243 shares with voting rights, representing 3.59% of the current 61,419,295 outstanding Ablynx.

The holdings attributable to Consonance CapMan GP LLC arise from holdings of undertakings for collective investments that are managed by Consonance Capital Management LP (Consonance Capital Master Account LP) and Consonance Capital Opportunity Fund Management LP (P Consonance Opportunities Ltd.). Consonance CapMan GP LLC is the general partner of Consonance Capital Management LP and Consonance Capital Opportunity Fund Management LP and has the power to vote the securities in the ordinary course of its investment management business. Consonance CapMan GP LLC is controlled by Mitchell Blutt.

Full versions of all transparency notifications are available on Ablynx website, under the section [Investors](#).

About Ablynx

[Ablynx](#) is a biopharmaceutical company engaged in the development of [Nanobodies](#), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than [45 proprietary and partnered programmes](#) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Lies Vanneste

Director IR

t: +32 (0)9 262 0137

m: +32 (0)498 05 35 79

e: lies.vanneste@ablynx.com

[Twitter](#) @AblynxABLX

Ablynx media relations:**Consilium Strategic Communications**

Mary-Jane Elliott, Philippa Gardner, Sukaina Virji

t: +44 (0)20 3709 5700

e: ablynx@consilium-comms.com

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.